PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Capsaicin - Pain (Neuropathic)

PAD Profile : Capsaicin - Pain (Neuropathic) Important

Keywords :
neuropathic pain, diabetic neuropathy, post-herpetic neuralgia, PHN
Brand Names Include :
Axsain
Important Information :
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)

Traffic Light Status

Status 1 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Cream
Important Information :
0.075% cream (Axsain brand) is licensed for this indication
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Red
Important
Formulations :
  • Patches
Important Information :
To be initiated by specialist pain care teams only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approves the use of capsaicin patches for the treatment of neuropathic pain when prescribed by specialist pain teams within a secondary care setting only.

 

The APC recommend a RED traffic light status for the use of capsaicin patches for this indication only.

 

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”

07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Capsaicin cream 0.075% (Axsain) is recommended at step 1 of the neuropathic pain guidelines for patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine).

See neuropathic pain guidelines for more information.

NOTE - capsaicin patches (Qutenza) are not recommended and have a non-formulary traffic light status.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.03.02. Rubefacients, topical NSAIDs, capsaicin and poultices
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More